Cost-effectiveness of enzyme replacement therapy for Fabry disease
about
The quality of economic evaluations of ultra-orphan drugs in Europe - a systematic reviewIdentification of an Allosteric Binding Site on Human Lysosomal Alpha-Galactosidase Opens the Way to New Pharmacological Chaperones for Fabry DiseaseReducing the costs of chronic kidney disease while delivering quality health care: a call to action.[Globosides as key players in the pathophysiology of Shiga toxin-associated acute kidney failure and Fabry disease].Cost-effectiveness of enzyme replacement therapy for type 1 Gaucher disease.Depletion of globosides and isoglobosides fully reverts the morphologic phenotype of Fabry diseaseGenetic stroke syndromesQuality of life in patients with Fabry disease: a systematic review of the literature.Variations in the GLA gene correlate with globotriaosylceramide and globotriaosylsphingosine analog levels in urine and plasma.Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries.Disease models for the development of therapies for lysosomal storage diseases.Sphingolipid lysosomal storage disorders.Unravelling the mechanism of action of enzyme replacement therapy in Fabry disease.Cost of renal replacement: how to help as many as possible while keeping expenses reasonable?Distribution-Weighted Cost-Effectiveness Analysis Using Lifetime Health Loss.Current and Future Treatments for Lysosomal Storage Disorders.Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease.Phenotype, disease severity and pain are major determinants of quality of life in Fabry disease: results from a large multicenter cohort study.Healthcare resource use and costs of managing children and adults with lysosomal acid lipase deficiency at a tertiary referral centre in the United Kingdom.The D313Y variant in the GLA gene - no evidence of a pathogenic role in Fabry disease.Neuropathic pain in a Fabry disease rat model.
P2860
Q26801751-B1D10DF5-2307-4208-BC3F-E5D218D030A0Q28553021-6C044479-D97E-4BAF-919C-F9A2E39EB56BQ30234324-6C8E5D96-9C6E-4D9B-AAFF-A9B2A6B99E35Q33418419-CE8245D4-E352-4C31-BB38-E8E10C2AD949Q33615777-8D65B9BC-AE49-4953-9D9C-AC437E321941Q34294988-BCD15F67-91C5-464B-B964-85502EB77123Q34522989-A5EA6480-2BAC-4960-B174-4B466C7CFED2Q35849151-80A692F4-65AF-478F-BD70-1AF599B1A6C0Q36691965-4E8FA6E9-651C-454B-831B-240A6B50A32DQ37441285-527CD31B-7A5A-4571-991C-C00E7C119F91Q37619231-BCEE4BE6-7E36-4360-B819-CD1FA52AEA7DQ38217766-61C0937F-FA0D-4E6C-981C-2A9999405420Q38421318-501DB661-671C-460F-B086-FF36076B7788Q38537462-611AC159-7F58-4DEB-BE32-BE2277410EDFQ38720758-1F827428-9DE7-4373-B843-180116E9747DQ45873942-1453C84A-B7B6-4C9B-A376-DD5A1C3C3C4EQ47121756-47F61D6F-3284-4959-BE6D-A25B6549E0DAQ47779398-50F8B17F-C520-4CE2-A0CA-C9AC064CD27CQ48114154-5D303268-E0E1-4560-A414-8E7BBFAE063DQ48180295-E2EDE367-C3D8-4C46-AA8A-9CD157C25813Q52347263-8E967013-E726-4E2B-B60E-7DD6625ED765
P2860
Cost-effectiveness of enzyme replacement therapy for Fabry disease
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Cost-effectiveness of enzyme replacement therapy for Fabry disease
@ast
Cost-effectiveness of enzyme replacement therapy for Fabry disease
@en
type
label
Cost-effectiveness of enzyme replacement therapy for Fabry disease
@ast
Cost-effectiveness of enzyme replacement therapy for Fabry disease
@en
prefLabel
Cost-effectiveness of enzyme replacement therapy for Fabry disease
@ast
Cost-effectiveness of enzyme replacement therapy for Fabry disease
@en
P2093
P2860
P356
P1476
Cost-effectiveness of enzyme replacement therapy for Fabry disease
@en
P2093
Carla E M Hollak
Gabor E Linthorst
Marcel G W Dijkgraaf
Saskia M Rombach
P2860
P2888
P356
10.1186/1750-1172-8-29
P577
2013-02-19T00:00:00Z
P5875
P6179
1013233795